↓ Skip to main content

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers

Overview of attention for article published in Molecular Cancer Therapeutics, July 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
58 tweeters

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Published in
Molecular Cancer Therapeutics, July 2018
DOI 10.1158/1535-7163.mct-17-1107
Pubmed ID
Authors

Roman Groisberg, David S. Hong, Jason Roszik, Filip Janku, Apostolia M. Tsimberidou, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah

Abstract

The European Society for Medical Oncology defines rare cancers as 5 or fewer cases per 100,000 persons/year. For many rare cancers, no standard of care exists, and treatment is often extrapolated. Identifying potentially targetable genomic alterations is a rational approach to improving treatment options. We sought to catalog these mutations in rare tumors and assess their clinical utility. For this retrospective analysis, we selected rare tumors from a dataset of patients who underwent clinical genomic profiling. Sarcomas were excluded. To index potentially actionable alterations, patients' reports were reviewed for mutations in cancer associated genes and pathways. Respective records were abstracted to appraise the benefit of using a targeted therapy approach. Actionable alterations were defined as targeted by a drug available on-label, off-label, or in clinical trials. The 95 patients analyzed had 40 different tumor subtypes, most common being adenoid cystic(13%), cholangiocarcinoma(7%), and metaplastic breast(6%). At least one genomic alteration was identified in 87 patients(92%). The most common identifiable mutations were in TP53(23%), KRAS(10%), PIK3CA(9%), CDKN2A/B(8%), BRAF(7%), MLL(7%), and ARID1A(6%). Thirty-six patients (38%) with 21 different tumors had at least one potentially actionable alteration. Thirteen patients received targeted therapy. Of these, 4 had a partial response, 6 had stable disease, and 3 had progressive disease as the best response. Addition of genomic profiling to management of rare cancers adds a potential line of therapy for cancers that have little or no standard of care. In our analysis, tumors with a BRAF alteration responded well to BRAF inhibitors.

Twitter Demographics

The data shown below were collected from the profiles of 58 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 55 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 15%
Other 6 11%
Researcher 6 11%
Student > Bachelor 4 7%
Student > Master 4 7%
Other 10 18%
Unknown 17 31%
Readers by discipline Count As %
Medicine and Dentistry 18 33%
Biochemistry, Genetics and Molecular Biology 6 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 2 4%
Other 3 5%
Unknown 20 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2022.
All research outputs
#1,060,298
of 22,120,510 outputs
Outputs from Molecular Cancer Therapeutics
#110
of 3,809 outputs
Outputs of similar age
#24,955
of 300,173 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#6
of 50 outputs
Altmetric has tracked 22,120,510 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,809 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.